413 related articles for article (PubMed ID: 30940536)
21. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.
McCaw EA; Hu H; Gomez GT; Hebb AL; Kelly ME; Denovan-Wright EM
Eur J Biochem; 2004 Dec; 271(23-24):4909-20. PubMed ID: 15606779
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid receptor 1 positive allosteric modulator ZCZ011 shows differential effects on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice.
Yadav-Samudrala BJ; Dodson H; Ramineni S; Kim E; Poklis JL; Lu D; Ignatowska-Jankowska BM; Lichtman AH; Fitting S
PLoS One; 2024; 19(6):e0305868. PubMed ID: 38913661
[TBL] [Abstract][Full Text] [Related]
23. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.
Glass M; van Dellen A; Blakemore C; Hannan AJ; Faull RL
Neuroscience; 2004; 123(1):207-12. PubMed ID: 14667455
[TBL] [Abstract][Full Text] [Related]
24. Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.
Naydenov AV; Sepers MD; Swinney K; Raymond LA; Palmiter RD; Stella N
Neurobiol Dis; 2014 Nov; 71():140-50. PubMed ID: 25134728
[TBL] [Abstract][Full Text] [Related]
25. Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Jun; 42(3):524-9. PubMed ID: 21406230
[TBL] [Abstract][Full Text] [Related]
26. Multiple Binding Sites Contribute to the Mechanism of Mixed Agonistic and Positive Allosteric Modulators of the Cannabinoid CB1 Receptor.
Saleh N; Hucke O; Kramer G; Schmidt E; Montel F; Lipinski R; Ferger B; Clark T; Hildebrand PW; Tautermann CS
Angew Chem Int Ed Engl; 2018 Mar; 57(10):2580-2585. PubMed ID: 29314474
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system.
Bari M; Battista N; Valenza M; Mastrangelo N; Malaponti M; Catanzaro G; Centonze D; Finazzi-Agrò A; Cattaneo E; Maccarrone M
FEBS J; 2013 Jul; 280(14):3376-88. PubMed ID: 23659592
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.
Horne EA; Coy J; Swinney K; Fung S; Cherry AE; Marrs WR; Naydenov AV; Lin YH; Sun X; Keene CD; Grouzmann E; Muchowski P; Bates GP; Mackie K; Stella N
Eur J Neurosci; 2013 Feb; 37(3):429-40. PubMed ID: 23167744
[TBL] [Abstract][Full Text] [Related]
29. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
30. Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model.
Straiker A; Mitjavila J; Yin D; Gibson A; Mackie K
Pharmacol Res; 2015 Sep; 99():370-6. PubMed ID: 26211948
[TBL] [Abstract][Full Text] [Related]
31. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
32. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.
Centonze D; Rossi S; Prosperetti C; Tscherter A; Bernardi G; Maccarrone M; Calabresi P
Biol Psychiatry; 2005 Jun; 57(12):1583-9. PubMed ID: 15953496
[TBL] [Abstract][Full Text] [Related]
33. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.
Ignatowska-Jankowska BM; Baillie GL; Kinsey S; Crowe M; Ghosh S; Owens RA; Damaj IM; Poklis J; Wiley JL; Zanda M; Zanato C; Greig IR; Lichtman AH; Ross RA
Neuropsychopharmacology; 2015 Dec; 40(13):2948-59. PubMed ID: 26052038
[TBL] [Abstract][Full Text] [Related]
34. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
Blázquez C; Chiarlone A; Sagredo O; Aguado T; Pazos MR; Resel E; Palazuelos J; Julien B; Salazar M; Börner C; Benito C; Carrasco C; Diez-Zaera M; Paoletti P; Díaz-Hernández M; Ruiz C; Sendtner M; Lucas JJ; de Yébenes JG; Marsicano G; Monory K; Lutz B; Romero J; Alberch J; Ginés S; Kraus J; Fernández-Ruiz J; Galve-Roperh I; Guzmán M
Brain; 2011 Jan; 134(Pt 1):119-36. PubMed ID: 20929960
[TBL] [Abstract][Full Text] [Related]
35. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
Lastres-Becker I; Berrendero F; Lucas JJ; Martín-Aparicio E; Yamamoto A; Ramos JA; Fernández-Ruiz JJ
Brain Res; 2002 Mar; 929(2):236-42. PubMed ID: 11864629
[TBL] [Abstract][Full Text] [Related]
36. Translational potential of allosteric modulators targeting the cannabinoid CB
Lu D; Immadi SS; Wu Z; Kendall DA
Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554
[TBL] [Abstract][Full Text] [Related]
37. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
38. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
Cawston EE; Redmond WJ; Breen CM; Grimsey NL; Connor M; Glass M
Br J Pharmacol; 2013 Oct; 170(4):893-907. PubMed ID: 23937487
[TBL] [Abstract][Full Text] [Related]
39. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy.
Garai S; Leo LM; Szczesniak AM; Hurst DP; Schaffer PC; Zagzoog A; Black T; Deschamps JR; Miess E; Schulz S; Janero DR; Straiker A; Pertwee RG; Abood ME; Kelly MEM; Reggio PH; Laprairie RB; Thakur GA
J Med Chem; 2021 Jun; 64(12):8104-8126. PubMed ID: 33826336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
